Ćelić Ivan, Bach-Rojecky Lidija, Merćep Iveta, Soldo Ana, Petrak Anja Kos, Bučan Ana
Department of Dual Diagnosis, University Psychiatric Hospital Vrapče, Bolnička Cesta 32, 10000, Zagreb, Croatia.
Department of Pharmacology, University of Zagreb Faculty of Pharmacy and Biochemistry, Domagojeva 2, 10000, Zagreb, Croatia.
Pain Ther. 2020 Jun;9(1):171-194. doi: 10.1007/s40122-020-00162-8. Epub 2020 Mar 14.
The objective of this systematic review is to reflect on assumptions in relation to codeine use in combination with other analgesics.
MEDLINE was searched according to the predetermined keywords and criteria. Only English language studies were taken into consideration and the outcome data of the final studies were extracted by two reviewers independently from each other and were checked by the third reviewer. Additionally, the available codeine-related Individual Case Safety Reports (ICSRs) retrieved from EudraVigilance were reviewed.
Sixteen placebo-controlled studies that involved 3378 subjects suffering from acute pain were analyzed for the efficacy of low-dose codeine (≤ 30 mg) combination products. Twelve of them found low-dose codeine combinations more efficient in relieving pain than the assigned comparator. According to 20 randomized clinical trials which included at least one dose of codeine (from 30 to 240 mg daily), the vast majority of reported side-effects were mild or moderate in severity. A total of 20 ICSRs for dependence were identified in the EudraVigilance database with codeine as a suspect drug for the 10-year time period for the European region.
Low-dose codeine combinations are effective after a single application in treating acute pain. Codeine in doses ≤ 30 mg and higher was considered safe since only mild to moderate side-effects were observed. There is no indication in the available sources which clearly links low doses of codeine to substance use disorder in non-dependent subjects.
本系统评价的目的是反思与可待因与其他镇痛药联合使用相关的假设。
根据预先确定的关键词和标准检索MEDLINE。仅纳入英文研究,最终研究的结果数据由两名审阅者相互独立提取,并由第三名审阅者进行核对。此外,还对从欧洲药品不良反应数据库(EudraVigilance)中检索到的可用的与可待因相关的个体病例安全报告(ICSR)进行了审查。
对16项涉及3378名急性疼痛患者的安慰剂对照研究进行了分析,以评估低剂量可待因(≤30mg)复方制剂的疗效。其中12项研究发现低剂量可待因复方制剂在缓解疼痛方面比指定的对照药物更有效。根据20项至少包含一剂可待因(每日30至240mg)的随机临床试验,报告的绝大多数副作用严重程度为轻度或中度。在欧洲药品不良反应数据库中,共识别出20份关于成瘾性的个体病例安全报告,在10年时间内可待因被列为可疑药物。
低剂量可待因复方制剂单次应用治疗急性疼痛有效。由于仅观察到轻度至中度副作用,≤30mg及更高剂量的可待因被认为是安全的。现有资料中没有明确表明低剂量可待因与非成瘾者的物质使用障碍有关。